| C Kozma Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study resultsWayne Macfadden Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA BMC Psychiatry 11:167. 2011 Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)Concetta Crivera Janssen Scientific Affairs, LLC, Raritan, New Jersey, USA BMC Psychiatry 11:168. 2011 Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and BelgiumTim Lambert Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA Ann Gen Psychiatry 10:10. 2011 Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extensionChris M Kozma University of South Carolina, Columbia, SC, USA Ann Gen Psychiatry 9:24. 2010 Economic benefit of a 1-day reduction in hospital stay for community-acquired pneumonia (CAP)C M Kozma University of South Carolina, Columbia, SC, USA J Med Econ 13:719-27. 2010 Change in employment status over 52 weeks in patients with schizophrenia: an observational studyC Kozma University of South Carolina, Columbia, SC, USA Curr Med Res Opin 27:327-33. 2011
| - Carla M Canuso
- Concetta Crivera
- Wayne Macfadden
- Lian Mao
- Cherilyn Desouza
- Stephen C Rodriguez
- Tim Lambert
- Riad D Dirani
- Joseph Peuskens
- An Jacobs
- Patrick Otten
- Riad Dirani
- Jose M Olivares
- Kasem S Akhras
|